

LISTING OF THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-4. (canceled)

5. (currently amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) a mature form of ~~the an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, NO:14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34;~~
- (b) a variant of a mature form of ~~the an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, NO:14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34,~~ wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, ~~provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;~~
- (c) ~~an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, NO:14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34;~~
- (d) a variant of ~~the an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, NO:14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 34,~~ wherein one or more amino acid residues in said variant differs from the amino acid sequence of ~~SEQ ID NO:14; said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and~~
- (e) ~~a nucleic acid fragment encoding at least a fragment portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, NO:14 selected from the group consisting of residues: 1-400, 450-520, 750-850, 1100-1200, 1250-1400, 1490-1750, 1760-2300, 2400-2600, and 2650-2725., 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and~~
- (f) ~~a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).~~

6-8. (canceled)

9. (currently amended) ~~An isolated~~ The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises ~~comprising~~ a nucleotide sequence selected from the group consisting of:

- (a) ~~a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, NO:13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35;~~

- (b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;
- (c) the complement of (a) or (b).
~~a nucleic acid fragment of (a); and~~
- (d) ~~a nucleic acid fragment of (b).~~

10. (currently amended) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, NO:13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35, or a complement of said nucleotide sequence.

11. (canceled)

12. (original) A vector comprising the nucleic acid molecule of claim 5.

13. (original) The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.

14. (original) A cell comprising the vector of claim 12.

15-38. (canceled)

39. (currently amended) A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically acceptable carrier.

40-41. (canceled)

42. (currently amended) A kit comprising in one or more containers, the pharmaceutical composition of claim 39.

43-49. (canceled)

50. (new) An isolated nucleic acid molecule comprising the complement of the nucleic acid molecule of claim 5.

51. (new) The nucleic acid molecule of claim 5 wherein the amino acid residue at position 28 of SEQ ID NO: 14 is Asp or Gly.

52. (new) The nucleic acid molecule of claim 5 wherein the amino acid residue at position 64 of SEQ ID NO: 14 is Val or Ala.

53. (new) The nucleic acid molecule of claim 5 wherein the amino acid residue at position 76 of SEQ ID NO: 14 is Ala or Thr.

Applicant: Gangolli (*as amended*)

USSN: 10/029,020

54. (new) A vector comprising the nucleic acid molecule of claim 9.
55. (new) The vector of claim 53, further comprising a promoter operably-linked to said nucleic acid molecule.
56. (new) A cell comprising the vector of claim 54.
57. (new) The nucleic acid molecule of claim 9 wherein the nucleotide residue at position 117 of SEQ ID NO: 13 is A or G.
58. (new) The nucleic acid molecule of claim 9 wherein the nucleotide residue at position 225 of SEQ ID NO: 13 is T or C.
59. (new) The nucleic acid molecule of claim 9 wherein the nucleotide residue at position 260 of SEQ ID NO: 13 is G or A.